Serum Kidney Injury Molecule 1 and β2-Microglobulin Perform as well as Larger Biomarker Panels for Prediction of Rapid Decline in Renal Function in Type 2 Diabetes

The goal of this study is to determine if biomarkers can be used to be predictive of renal disease progression in diabetes as a method to enrich clinical trials with patients most at risk. From the SUMMIT (Surrogate Markers for Micro- and Macrovascular Hard Endpoints for Innovative Diabetes Tools) programme, the authors originally identified 207 serum biomarkers that is predictive of renal function decline. From these 207 biomarkers, the authors selected 42 biomarkers using forward selection and least absolute shrinkage and selection operator (LASSO) penalized regression approaches. The 42 biomarkers were split into smaller panels and tested for the ability to predict performance similar to the larger panels.

Read More

A New Generation of Biomarkers for Detecting Early Signs of Kidney Damage

Nephrotoxicity is a major problem in the preclinical and clinical setting that results in the failure of candidate compounds throughout the drug-development cycle. An article in this month’s GEN outlines the development of a new generation of biomarkers for drug-induced toxicity that provides greater sensitivity and earlier detection than previous methods. https://www.genengnews.com/gen-articles/fighting-kidney-toxicity-the-case-for-better-biomarkers/5178/

The Need for Additional Translational Biomarkers

The authors of this paper review the various methods of safety biomarker discovery and development, and challenge researchers to advance the use of safety biomarkers that are indicative of drug-induced toxicity. This type of research typically spans both preclinical and clinical development programs. Having the ability to identify translational safety biomarkers on the same technology platform is one of Myriad RBM’s strengths. Read the Paper Here
1 2